Similarly, fibroblast growth factor 21 (FGF21) analogs, such as pegbelfermin, have progressed into clinical development, showing beneficial effects on lipid metabolism, insulin sensitivity, and hepatic steatosis in obese individuals with type 2 diabetes [98]. This evidence concerns the gene FGF21 and Hepatic steatosis.